Progress in translating bioinorganic nanoplatform discoveries into clinical lung cancer care: Overcoming limitations, targeted drug delivery and imaging

Lung cancer remains as the leading cause of cancer-related fatalities globally, posing significant challenges to conventional treatment methods, particularly in advanced stages where limitations and adverse effects are prevalent. Nanotechnology offers promising solutions to enhance lung cancer therapy. Inorganic nanomaterials, such as metal nanoparticles, rare earth elements, and carbonaceous materials, exhibit unique properties that can address these challenges. Metal nanoparticles facilitate targeted drug delivery, biosensing, and imaging, while rare earth elements demonstrate selective cytotoxic effects and imaging capabilities. Carbonaceous materials find applications in biosensing and drug delivery, including carbon ion radiotherapy. These advancements in inorganic nanomaterials present an opportunity to revolutionize lung cancer treatment, potentially leading to improved outcomes and better patient well-being. This paper focuses on recent progress in utilizing inorganic nanomaterials for treating lung cancer, aiming to provide a clearer understanding of their benefits compared to conventional treatments, along with an in-depth examination of their associated limitations and adverse effects.